Sign In

Janice Marie McCourt, BS, RPh, MBA, CLP

Chief Business Officer at Lyvgen Biopharmaceuticals

Janice Marie McCourt is a seasoned commercial executive with over 24 years of experience in the biotech and pharmaceutical industries.1 She currently serves as the Chief Executive Officer and Board Member at Hudson Therapeutics, the US subsidiary of Shaperon, a South Korean biotech company.34

Professional Background

Janice has an impressive educational background, holding a BS, RPh, and MBA, as well as completing the Harvard Executive Leadership Program.1 Her expertise spans various areas, including:

  • Corporate and business development
  • Product launch
  • Commercial operations
  • Industrial pharmacy
  • Finance and investor relations

Career Highlights

Throughout her career, Janice has achieved significant milestones:

  • Successfully raised over $3.5 billion in investment and partnering deals1
  • Executed multiple transactions involving out-licensing, in-licensing, and partnering with major biotech and pharmaceutical organizations1
  • Built and managed commercial teams
  • Launched blockbuster products in oncology markets and other therapeutic areas1

Current Role at Hudson Therapeutics

As the CEO of Hudson Therapeutics, Janice's responsibilities include:

  • Leading the Business Development division3
  • Fostering research collaborations and licensing opportunities3
  • Overseeing global clinical trials2
  • Managing investor relations2
  • Developing commercial strategy2

Industry Involvement

Janice is actively involved in industry events and initiatives:

  • Participating in the 2024 BIO International Convention in San Diego2
  • Leading meetings with potential pharmaceutical partners and new collaborators2
  • Discussing technology transfer for various treatments, including Nugel (Atopic Dermatitis), Nucerin (Alzheimer's Disease), and Papiliximab (dual-target Nanobody Antibody)2

Focus Areas

Under Janice's leadership, Hudson Therapeutics is exploring various therapeutic areas, including:

  • Atopic dermatitis
  • Alzheimer's disease
  • Oncology
  • Ulcerative colitis
  • Crohn's Disease
  • MASH (Metabolic dysfunction-associated steatohepatitis)
  • Obesity
  • Veterinary medicine (companion animals)2

Janice Marie McCourt's extensive experience and leadership in the biotech and pharmaceutical industries make her a valuable asset to Hudson Therapeutics and Shaperon as they work to develop innovative therapies for various medical needs.

Highlights

May 30 · businesswire.com
Shaperon & Hudson to Participate in the 2024 Bio International ...
Shaperon & Hudson to Participate in the 2024 Bio International ...

Related Questions

What are Janice Marie McCourt's key achievements at Hudson Therapeutics?
How did Janice Marie McCourt contribute to the success of Lyvgen Biopharmaceuticals?
What are the main projects Janice Marie McCourt is currently working on at Hudson Therapeutics?
What is the significance of Shaperon's unique mechanism of action in inflammasome inhibitors?
How does Hudson Therapeutics plan to utilize the BIO International Convention for business development?
Janice Marie McCourt, BS, RPh, MBA, CLP
Janice Marie McCourt, BS, RPh, MBA, CLP, photo 1
Janice Marie McCourt, BS, RPh, MBA, CLP, photo 2
Add to my network

Experience

Chief Business Officer at Lyvgen Biopharmaceuticals

Education

Harvard Executive Leadership Program

Location

Greater Boston